Fund invests $200 million in biotech stock
Stock price increased by 30% after Phase 3 results
Investment reflects confidence in biotech sector
Briefing: This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough
Strategic angle: A significant investment in a biotech stock following a major clinical success.